Glenn S Tillotson

Glenn Tillotson has 30+ years of pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management, and global launch programs. Dr. Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin, and most recently solithromycin. Glenn has held several key committee positions at the American College of Chest Physicians, he is on the Scientific Steering Committee for the GTCBio the Annual Summit on Anti-infective Partnering. Currently, Dr. Tillotson has published >150 peer-reviewed manuscripts, presented >270 scientific posters, and is on several journals Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine Expert Reviews in Anti-Infective Therapy, and F1000.